FIELD: medicine.
SUBSTANCE: the present innovation deals with increasing body resistance to infection in case of oncological and autoimmune diseases, for accelerating the restoration of normal functioning in patient's organs and tissues affected due to medicinal side effect, for increasing resistance to toxic substances. Thus, one should prescribe ascorbigen at the dosage of 10 mg/kg for 5-30 d. The method provides increased inspecific resistance to infectious and toxic agents, enables to decrease the risk for the development of severe sickness and accelerate recovery in patients.
EFFECT: higher efficiency.
3 cl, 2 dwg, 6 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| AGENT "LIZOLAKT" POTENTIATING ANTITUMOR ACTIVITY OF CYTOTOXIC PREPARATIONS | 2006 |
|
RU2311196C1 |
| AGENT AND METHOD OF ANTITUMOR ACTIVITY INCREASE AND CYTOSTATIC THERAPY BY-SIDE EFFECTS DECREASE | 1995 |
|
RU2078578C1 |
| MEDICATION, WHICH POSSESES IMMUNOSTIMULATING ACTIVITY | 2009 |
|
RU2403054C1 |
| PHARMACEUTICAL COMPOSITION BASED ON 6-[(4-METHYL-1-1-PIPERAZINYL)METHYL]-INDOLO[1',7':1,2,3]PYRROLO[3',4':6,7]AZEPINO[4,5-b]INDOLE-1,3(2H,10 H)-DIONE AS ANTI-TUMOUR MEDICATION | 2013 |
|
RU2523387C1 |
| MEDICATION POSSESSING IMMUNOTROPIC ACTIVITY | 2009 |
|
RU2406524C1 |
| METHOD OF LEUKOPOIESIS STIMULATION | 1993 |
|
RU2078581C1 |
| CIS-CHLORODIAMINE-1,3-DIMETHYLXANTHINE PLATINUM (II) CHLORIDE DIHYDRATE | 1990 |
|
SU1790190A1 |
| PHARMACEUTICAL COMPOSITION BASED ON PALLADIUM COMPOUND | 2015 |
|
RU2613305C2 |
| AGENT POSSESSING IMMUNOCORRECTIVE ACTION IN CYTOSTATIC IMMUNOSUPPRESSION | 2011 |
|
RU2482861C1 |
| METHOD FOR MODELLING ACUTE DYNAMIC INTESTINAL OBSTRUCTION IN EXPERIMENT | 2019 |
|
RU2739858C1 |
